Identification of miR‑195‑3p as an oncogene in RCC

Jin,Lu; Li,Xi; Li,Yifan; Zhang,Zeng; He,Tao; Hu,Jia; Liu,Jiaju; Chen,Mingwei; Shi,Min; Jiang,Zhimao; Gui,Yaoting; Yang,Shangqi; Mao,Xiangming; Lai,Yongqing

doi:10.3892/mmr.2017.6198

Identification of miR‑195‑3p as an oncogene in RCC

Authors:
- Lu Jin
- Xi Li
- Yifan Li
- Zeng Zhang
- Tao He
- Jia Hu
- Jiaju Liu
- Mingwei Chen
- Min Shi
- Zhimao Jiang
- Yaoting Gui
- Shangqi Yang
- Xiangming Mao
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Department of Urology, Anhui Medical University, Hefei, Anhui 230032, P.R. China, The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Shenzhen, Guangdong 518036, P.R. China
Published online on: February 13, 2017 https://doi.org/10.3892/mmr.2017.6198
Pages: 1916-1924

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is increasing evidence that the deregulation of microRNAs (miRNAs; miRs) contributes to tumorigenesis. Previous studies have shown that miR‑195 is downregulated in various types of cancer. The present study aimed to investigate the function and expression levels of miR‑125b. Results of qPCR revealed that miR‑195‑3p, the mature sequence of miR‑195, was upregulated in renal cell carcinoma (RCC) tissues and cell lines (786‑O, 769P and ACHN). This indicated that the function and role of miR‑195‑3p may differ in different types of tumor. To assess the function of miR‑195‑3p in RCC cell lines, cell proliferation was examined using MTT and CCK‑8 assays, mobility was assessed using a cell scratch assay, Transwell migration assay and invasion assay, and apoptosis was examined using flow cytometry. These assessments were also performed in cells with upregulated or downregulated miR‑195‑3p via transfection with synthesized miR‑195‑3p mimic or inhibitor. The results revealed that the overexpression of miR‑195‑3p promoted 786‑O and ACHN RCC cell proliferation, migration and invasion, and inhibited cell apoptosis, whereas the downregulation of miR‑195‑3p suppressed cell proliferation, migration and invasion, and induced cell apoptosis. These results indicated that miR‑195‑3p was associated with the tumorigenesis of RCC, with further investigations to focus on the pathway and use of miR‑195‑3p as a clinical biomarker for RCC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sun TY, Xie HJ, Li Z and Kong LF: Expression of FOXC2 in renal cell carcinoma and its relationship to clinical pathological features. Int J Clin Exp Med. 8:13388–13392. 2015.PubMed/NCBI
3	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
4	Tostain J, Li G, Gentil-Perret A and Gigante M: Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur J Cancer. 46:3141–3148. 2010. View Article : Google Scholar : PubMed/NCBI
5	Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F and Takenaka A: Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 44:53–58. 2014.PubMed/NCBI
6	Wang X, Wang J, Ma H, Zhang J and Zhou X: Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 29:919–927. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I and Yamashita S: miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
8	Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
9	Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu H, Xiao B, Jiao CH, Tang NN, Ma JJ, et al: Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett. 587:3471–3479. 2013. View Article : Google Scholar : PubMed/NCBI
11	Fei X, Qi M, Wu B, Song Y, Wang Y and Li T: MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett. 586:392–397. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhao C, Qi L, Chen M, Liu L, Yan W, Tong S and Zu X: microRNA-195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription-3 signaling. Exp Ther Med. 10:1103–1108. 2015.PubMed/NCBI
13	Mao JH, Zhou RP, Peng AF, Liu ZL, Huang SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett. 4:1125–1129. 2012.PubMed/NCBI
14	Li Z, Wang H, Wang Z and Cai H: MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1. Tumour Biol. 37:6457–6463. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yi Z, Fu Y, Zhao S, Zhang X and Ma C: Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862. 2010. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−Delta Delta C (T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Liu L, Chen L, Xu Y, Li R and Du X: microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 400:236–240. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, Zhou H and Qu LH: MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 14:278–287. 2012. View Article : Google Scholar : PubMed/NCBI
19	Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2 and CDC42. Hepatology. 58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
21	Luo Q, Wei C, Li X, Li J, Chen L, Huang Y, Song H, Li D and Fang L: MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep. 31:1096–1102. 2014.PubMed/NCBI
22	Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guanjian L, Yujie L and Yunchao H: MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett. 347:65–74. 2014. View Article : Google Scholar : PubMed/NCBI
23	Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 Inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
24	Guo J, Wang M and Liu X: MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res. 34:912015. View Article : Google Scholar : PubMed/NCBI
25	Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y, Liu Y, Li S, Liang Z, Xu X, et al: MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. J Transl Med. 13:2892015. View Article : Google Scholar : PubMed/NCBI
26	Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L, Lu K, Tao T, Zhang X and Huang Y: miR-195 inhibits EMT by targeting FGF2 in prostate cancer cells. PLoS One. 10:e01440732015. View Article : Google Scholar : PubMed/NCBI
27	Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q, Yang K, Zheng X and Xie L: Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett. 586:442–447. 2012. View Article : Google Scholar : PubMed/NCBI
28	Yang X, Yu J, Yin J, Xiang Q, Tang H and Lei X: MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 67:645–651. 2012.PubMed/NCBI
29	Jiang HL, Yu H, Ma X, Xu D, Lin GF, Ma DY and Jin JZ: MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells. Tumour Biol. 35:6955–6960. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zheng C, Li J, Wang Q, Liu W, Zhou J, Liu R, Zeng Q, Peng X, Huang C, Cao P, et al: MicroRNA-195 functions as a tumor suppressor by inhibiting CBX4 in hepatocellular carcinoma. Oncol Rep. 33:1115–1122. 2015.PubMed/NCBI
31	Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI
32	Amer M, Elhefnawi M, El-Ahwany E, Awad AF, Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. Tumour Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
33	Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One. 8:e601552013. View Article : Google Scholar : PubMed/NCBI
34	Yang B, Tan Z and Song Y: Study on the molecular regulatory mechanism of MicroRNA-195 in the invasion and metastasis of colorectal carcinoma. Int J Clin Exp Med. 8:3793–3800. 2015.PubMed/NCBI
35	Wang L, Qian L, Li X and Yan J: MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. Mol Med Rep. 10:473–478. 2014.PubMed/NCBI
36	Tashkandi H, Shah N, Patel Y and Chen H: Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience. 2:924–929. 2015.PubMed/NCBI
37	Zhang Y, Zhang D, Wang F, Xu D, Guo Y and Cui W: Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep. 5:179422015. View Article : Google Scholar : PubMed/NCBI
38	Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL and Zhang YK: Serum microRNA-195 is down-regulated in breast cancer: A potential marker for the diagnosis of breast cancer. Mol Biol Rep. 41:5913–5922. 2014. View Article : Google Scholar : PubMed/NCBI
39	Cai H, Zhao H, Tang J and Wu H: Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res. 194:505–510. 2015. View Article : Google Scholar : PubMed/NCBI
40	Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG and Sidhu SB: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI
41	Yang X, Yin J, Yu J, Xiang Q, Liu Y, Tang S, Liao D, Zhu B, Zu X, Tang H and Lei X: miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep. 27:250–257. 2012.PubMed/NCBI
42	Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W, Jiang X, Zhang C and Qu J: MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol. 230:535–545. 2015. View Article : Google Scholar : PubMed/NCBI
43	Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian J and Weng Y: Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep. 30:877–889. 2013.PubMed/NCBI
44	Zhu J, Ye Q, Chang L, Xiong W, He Q and Li W: Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2. Int J Clin Exp Med. 8:9142–9148. 2015.PubMed/NCBI